Shots:

• Jounce to receive $85M up front- $685B as clinical- regulatory- and commercial milestone payments- $35M equity investment at a premium in Jounce upon closing along with royalties on global sales of therapies including JTX-1811. The transaction is expected to be closed in H2’20
• Jounce will lead the development of JTX-1811 through IND clearance- and thereafter- Gilead will be solely responsible to develop the therapy
• JTX-1811 is a mAb- targeting CCR8 and selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells

­ Ref: Gilead | Image: Dragon Images